Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects.
Aim:
The aim of the current study was to explore the psychedelic experiences and sustained impact of ketamine in major depressive disorder.
Methods:
In the current study, ketamine (0.44 mg/kg) was administered to 32 volunteers with major depressive disorder in a crossover design with the active-placebo remifentanil, in a magnetic resonance imaging (MRI) environment. The 11-dimension altered states of consciousness questionnaire and individual qualitative interviews were used to capture the acute psychedelic experience. The Montgomery-Asberg Depression Rating Scale and further interviewing explored lasting effects. The second qualitative interview took place ⩾3 weeks post-ketamine.
Results:
Greater antidepressant response (reduction in Montgomery-Asberg Depression Rating Scale at 24 h) correlated with the 11-dimension altered states of consciousness dimensions: spirituality, experience of unity, and insight. The first qualitative interview revealed that all participants experienced perceptual changes. Additional themes emerged including loss of control and emotional and mood changes. The final interview showed evidence of a psychedelic afterglow, and changes to perspective on life, people, and problems, as well as changes to how participants felt about their depression and treatments.
Conclusions:
The current study provides preliminary evidence for a role of the psychedelic experience and afterglow in ketamine’s antidepressant properties. Reflexive thematic analysis provided a wealth of information on participants’ experience of the study and demonstrated the psychedelic properties of ketamine are not fully captured by commonly used questionnaires.
AdlerCMGoldbergTEMalhotraAK, et al. (1998) Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry43: 811–816.
2.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Washington, DC: APA.
3.
BadosABalaguerGSaldañaC (2007) The efficacy of cognitive–behavioral therapy and the problem of drop-out. J Clin Psychol63: 585–592.
4.
BarrettFSBradstreetMPLeoutsakosJ-MS, et al. (2016) The challenging experience questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol30: 1279–1295.
5.
BarrettFSJohnsonMWGriffithsRR (2015) Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol29: 1182–1190.
6.
BenjaminiYHochbergY (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B57: 289–300.
7.
BermanRMCappielloAAnandA, et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry47: 351–354.
8.
BowdleATRadantADCowleyDS, et al. (1998) Psychedelic effects of ketamine in healthy volunteers relationship to steady-state plasma concentrations. Anesthesiology88: 82–88.
9.
BraunVClarkeV (2006) Using thematic analysis in psychology. Qual Res Psychol3: 77–101.
10.
BraunVClarkeV (2019) Reflecting on reflexive thematic analysis. Qual Res Sport Exerc Health11: 589–597.
11.
BraunVClarkeV (2020) One size fits all? What counts as quality practice in (reflexive) thematic analysis?Qual Res Psychol. Epub ahead of print 12 August 2020. DOI: 10.1080/14780887.2020.1769238.
12.
Carhart-HarrisRLBolstridgeMDayCMJ, et al. (2018a) Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology235: 399–408.
13.
Carhart-HarrisRLErritzoeDWilliamsT, et al. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A109: 2138–2143.
14.
Carhart-HarrisRLFristonK (2019) REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacol Rev71: 316–344.
15.
Carhart-HarrisRLLeechRHellyerPJ, et al. (2014) The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci8: 20.
16.
Carhart-HarrisRLNuttDJ (2017) Serotonin and brain function: a tale of two receptors. J Psychopharmacol31: 1091–1120.
17.
Carhart-HarrisRLRosemanLHaijenE, et al. (2018b) Psychedelics and the essential importance of context. J Psychopharmacol32: 725–731.
18.
ChenXShuSBaylissDA (2009) HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci29: 600–609.
19.
DittrichA. (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry31: 80–84.
20.
DoreJTurnipseedBDwyerS, et al. (2019) Ketamine Assisted Psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoact Drugs51: 189–198.
21.
FondGLoundouARabuC, et al. (2014) Ketamine administration in depressive disorders: A systematic review and meta-analysis. Psychopharmacology231: 3663–3676.
22.
GilbertJRZarateJrCA (2020) Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation. Pharmacol Biochem Behav189: 172856.
23.
GriffithsRRJohnsonMWCarducciMA, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol30: 1181–1197.
24.
GriffithsRRRichardsWAMcCannU, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology187: 268–283.
25.
HaijenECHMKaelenMRosemanL, et al. (2018) Predicting responses to psychedelics: A prospective study. Front Pharmacol9: 897.
26.
HealyCJ (2021) The acute effects of classic psychedelics on memory in humans. Psychopharmacology (Berl) 238: 1–15.
27.
HoneyGDHoneyRAEO’LoughlinC, et al. (2005) Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: An fMRI study. Cereb Cortex15: 749–759.
28.
IngramREHollonSD (1986) Cognitive therapy for depression from an information processing perspective. In:Information Processing Approaches to Clinical Psychology. Orlando, FL, US: Academic Press, pp.26–284.
29.
JansenK (2004) Ketamine: Dreams and Realities. Sarasota, FL: Multidisciplinary Association for Psychedelic Studies.
30.
JohnsonMWHendricksPSBarrettFS, et al. (2019) Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther197: 83–102.
31.
KallioHPietiläA-MJohnsonM, et al. (2016) Systematic methodological review: Developing a framework for a qualitative semi-structured interview guide. J Adv Nurs72: 2954–2965.
32.
KishimotoTChawlaJMHagiK, et al. (2016) Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: A meta-analysis of efficacy, safety and time trajectories. Psychol Med46: 1459–1472.
33.
KohrsRDurieuxME (1998) Ketamine: Teaching an old drug new tricks. Anesth Analg87: 1186–1193.
34.
KrupitskyEBurakovARomanovaT, et al. (2002) Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. J Subst Abuse Treat23: 273–283.
35.
KrupitskyEMGrinenkoAY (1997) Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. J Psychoact Drugs29: 165–183.
36.
KrystalJHKarperLPSeibylJP, et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry51: 199–214.
37.
LuckenbaughDANiciuMJIonescuDF, et al. (2014) Do the dissociative side effects of ketamine mediate its antidepressant effects?J Affect Disord159: 56–61.
38.
LyCGrebACCameronLP, et al. (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep23: 3170–3182.
39.
McGirrABerlimMTBondDJ, et al. (2014) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med45: 693–704.
40.
McMillanRMuthukumaraswamyS (2020) The neurophysiology of ketamine: An integrative review. Rev Neurosci31: 457–503.
41.
McMillanRSumnerRForsythA, et al. (2020) Simultaneous EEG/fMRI recorded during ketamine infusion in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry99: 109838.
42.
MajićTSchmidtTTGallinatJ (2015) Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?J Psychopharmacol29: 241–253.
43.
MaslowAH (1961) Peak experiences as acute identity experiences. Am J Psychoanal21: 254–262.
44.
MathaiDSMeyerMJStorchEA, et al. (2020) The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. J Affect Disord264: 123–129.
45.
MintoCFSchniderTWEganTD, et al. (1997a) Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology86: 10–23.
46.
MintoCFSchniderTWShaferSL (1997b) Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology86: 24–33.
47.
MorganCJACurranHV (2006) Acute and chronic effects of ketamine upon human memory: A review. Psychopharmacology188: 408–424.
48.
MurroughJWIosifescuDVChangLC, et al. (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry170: 1134–1142.
49.
NiciuMJLuckenbaughDAIonescuDF, et al. (2014) Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry75: e417–e423.
50.
NuttD (2019) Psychedelic drugs-a new era in psychiatry?Dialogues Clin Neurosci21: 139–147.
51.
PahnkeWN (1966) Drugs and mysticism. Int J Parapsychol8: 295–313.
52.
PahnkeWN (1969) The psychedelic mystical experience in the human encounter with death. Harv Theol Rev62: 1–21.
53.
PassieTKarstMWieseB, et al. (2005) Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man. Neuropsychobiology51: 226–233.
54.
PhillipsJLNorrisSTalbotJ, et al. (2019) Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. Am J Psychiatry176: 401–409.
55.
ReiffCMRichmanEENemeroffCB, et al. (2020) Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry177: 391–410.
56.
RenaudJRussellJJMyhrG. (2014) Predicting who benefits most from cognitive-behavioral therapy for anxiety and depression. J Clin Psychol70: 924–932.
57.
RosemanLHaijenEIdialu-IkatoK, et al. (2019) Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. J Psychopharmacol33: 1076–1087.
58.
RosemanLNuttDJCarhart-HarrisRL (2018) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol8: 974.
59.
SanacoraGSchatzbergAF (2015) Ketamine: Promising path or false prophecy in the development of novel therapeutics for mood disorders?Neuropsychopharmacology40: 259–267.
60.
SchenbergEE (2018) Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Front Pharmacol9: 733.
61.
SleighJHarveyMVossL, et al. (2014) Ketamine–more mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care4: 76–81.
62.
SosPKlirovaMNovakT, et al. (2013) Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett34: 287–293.
63.
StuderusEGammaAVollenweiderFX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One5: e12412.
64.
SumnerRLMcMillanRSpriggsMJ, et al. (2020a) Ketamine enhances visual sensory evoked potential long-term potentiation in patients with major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging5: 45–55.
65.
SumnerRLMcMillanRSpriggsMJ, et al. (2020b) Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors. Eur Neuropsychopharmacol38: 73–85.
66.
TeasdaleJDSegalZWilliamsJMG (1995) How does cognitive therapy prevent depressive relapse and why should attentional control (mindfulness) training help?Behav Res Ther33: 25–39.
67.
TongASainsburyPCraigJ (2007) Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. Int J Qual Health Care19: 349–357.
68.
ValentineGWMasonGFGomezR, et al. (2011) The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Res191: 122–127.
69.
VidalSGex-FabryMBancilaV, et al. (2018) Efficacy and safety of a rapid intravenous injection of ketamine 0.5 mg/kg in treatment-resistant major depression: An open 4-week longitudinal study. J Clin Psychopharmacol38: 590–597.
70.
VollenweiderFXKometerM (2010) The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci11: 642.
71.
WattsRDayCKrzanowskiJ, et al. (2017) Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. J Humanist Psychol57: 520–564.
72.
WattsRLuomaJB (2020) The use of the psychological flexibility model to support psychedelic assisted therapy. J Contextual Behav Sci15: 92–102.
73.
WilkinsonSTWrightDFasulaMK, et al. (2017) Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother Psychosom86: 162–167.
74.
WilliamsJBKobakKA (2008) Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry192: 52–58.
75.
WolffMEvensRMertensLJ, et al. (2020) Learning to let go: A cognitive-behavioral model of how psychedelic therapy promotes acceptance. Front Psychiatry11: 5.
76.
ZarateCAJr.SinghJBCarlsonPJ, et al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry63: 856–864.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
